Our Vaccines
We are developing safe vaccines against a range of human disease threats.
We have developed the first polydrug vaccine solution to combat xylazine, nitazenes, and fentanyl.
Using our patented techniques we have created a novel vaccine to globally combat Lyme Disease
We are developing the first vaccine capable of protection against Chlamydia using an inter-vaginal gel
Our Technology
Our adjuvanting solutions readily interact with the mucosa for effective oral, nasal, and vaginal delivery of vaccines and providing an alternative to conventional injections.
Our vaccine platform is constructed using multivalent technology for polyantigen presentation. This approach produces cross-reactive antibodies that are effective against a wide range of pathogen variants.
We are developing new, safe carbohydrate-based adjuvants using our patented in vitro glycosylation platform. Our adjuvant solutions can be covalently attached to any protein-based vaccine resulting a self-adjuvanting formulation capable of robust B cell and T cell responses.
Our patented in vitro glycosylation platform can enhance proteins, enzymes, and immunogens by providing a universal glycosylation method that does not compromise bioactivity.